Related Experiment Video
Updated: Sep 16, 2025
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
8.2K
Navigating Fabry Disease in a Military Aviator
Aerospace Medicine and Human Performance
|July 11, 2025
Summary
Fabry disease (FD), a rare genetic disorder, can be managed in military aviators. Early diagnosis and chaperone therapy allowed a pilot with FD to return to flying duties under strict monitoring.
Area of Science:
- Genetics
- Aerospace Medicine
- Lysosomal Storage Disorders
Background:
- Fabry disease (FD) is an X-linked lysosomal storage disorder caused by alpha-galactosidase A (alpha-Gal A) deficiency.
- FD leads to glycosphingolipid accumulation, causing systemic symptoms including neurological, renal, and cardiovascular issues.
- The incidence of FD may be underreported, with no prior documented cases in aviators.
Observation:
- A 30-year-old U.S. Air Force pilot with a family history of FD was diagnosed with a pathogenic galactosidase alpha gene variant.
- Initial evaluations revealed early FD with proteinuric kidney disease and normal neurological findings.
- The pilot received lisinopril, clopidogrel, and migalastat chaperone therapy.
Findings:
- Treatment with migalastat resulted in improved biochemical parameters and clinical stability.
- The patient tolerated the therapy well.
- After 8 months of multidisciplinary monitoring, the pilot received an aeromedical waiver and returned to flying duties.
Implications:
- FD patients, despite aeromedical risks like stroke, may be eligible for restricted flight duties.
- Close monitoring and multidisciplinary care are crucial for aviators with FD.
- Individualized waivers and novel therapies can support aviators with FD, balancing safety and operational needs.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
38
06:59Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
77
Related Concept Videos
01:24Cystic Fibrosis: Management
227
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
227
01:26Mitral Stenosis III: Medical Management
28
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
28
01:23Cystic Fibrosis: Pathogenesis
369
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
369
01:26Flail Chest-II
240
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
240
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
209
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
209
01:25Aortic Regurgitation III: Medical Management
51
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
51